Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 14/20 | 0.44 |
| ▸ | LPAR2 | Q9HBW0 | 12/20 | 0.44 |
| ▸ | LPAR1 | Q92633 | 7/20 | 0.37 |
| ▸ | LPAR6 | P43657 | 4/20 | 0.34 |
| ▸ | LPAR4 | Q99677 | 4/20 | 0.34 |
| ▸ | LPAR5 | Q9H1C0 | 4/20 | 0.34 |
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA3 | P07451 | 2/20 | 0.32 |
| ▸ | CA4 | P22748 | 2/20 | 0.32 |
| ▸ | CA6 | P23280 | 2/20 | 0.32 |
| ▸ | CA5A | P35218 | 2/20 | 0.32 |
| ▸ | CA7 | P43166 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.32 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.32 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28089409 | 0.83 | — | — | |
| Dodecylamine SCHEMBL11065806 | 0.82 | LPAR3 (0.62) | LPAR3LPAR2LPAR1DNM1TSHR | |
| SCHEMBL31373209 | 0.82 | LPAR3 (0.67) | LPAR3LPAR2LPAR1LPAR6LPAR4 | |
| SCHEMBL8467645 | 0.82 | LPAR3 (0.67) | LPAR3LPAR2LPAR1LPAR6LPAR4 | |
| SCHEMBL13748550 | 0.79 | LPAR3 (0.47) | LPAR3LPAR2LPAR1CA12CA1 | |
| SCHEMBL25559472 | 0.79 | LPAR3 (0.61) | LPAR3LPAR2LPAR1LPAR6LPAR4 | |
| SCHEMBL6933398 | 0.79 | LPAR3 (0.61) | LPAR3LPAR2LPAR1LPAR6LPAR4 | |
| Dodecylamine SCHEMBL11084017 | 0.78 | LPAR3 (0.57) | LPAR3LPAR2LPAR1DNM1TSHR | |
| SCHEMBL19237471 | 0.76 | LPAR3 (0.44) | LPAR3LPAR2LPAR1LMNATSHR | |
| SCHEMBL2755680 | 0.76 | LPAR3 (0.44) | LPAR3LPAR2LPAR1LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230287413-A1 | TARGETED DELIVERY OF AN INHIBITOR OF MIR-21 TO MACROPHAGES FOR THE TREATMENT OF PULMONARY FIBROSIS | Technische Universität München (DE) | 2023-09-14 | — | — | US | disclosed |
| US-20230158156-A1 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | FLAGSHIP PIONEERING, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| US-20210228615-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2021-07-29 | — | — | US | disclosed |
| US-8785151-B2 | Biosynthetically generated pyrroline-carboxy-lysine and site specific protein modifications via chemical derivatization of pyrroline-carboxy-lysine and pyrrolysine residues | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2014-07-22 | — | — | US | disclosed |
| EP-2356092-B1 | BIOSYNTHETICALLY GENERATED PYRROLINE-CARBOXY-LYSINE AND SITE SPECIFIC PROTEIN MODIFICATIONS VIA CHEMICAL DERIVATIZATION OF PYRROLINE-CARBOXY-LYSINE AND PYRROLYSINE RESIDUES | IRM LLC (BM) | 2014-04-16 | — | — | EP | disclosed |
| US-20110262963-A1 | BIOSYNTHETICALLY GENERATED PYRROLINE-CARBOXY-LYSINE AND SITE SPECIFIC PROTEIN MODIFICATIONS VIA CHEMICAL DERIVATIZATION OF PYRROLINE-CARBOXY-LYSINE AND PYRROLYSINE RESIDUES | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2011-10-27 | — | — | US | disclosed |
| US-7902160-B2 | ENA nucleic acid drugs modifying splicing in mRNA precursor | Matsuo, Masafumi (JP) | 2011-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210228615-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | SMN1; SMN2, RBM17, RBM22 | LPAR3 1231/4885LPAR2 919/4885LPAR1 1401/4885 |
| US-20230158156-A1 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | EFTUD2, SNRPE, DDX21 | LPAR3 2435/4885LPAR2 1934/4885LPAR1 2796/4885 |
| US-20110262963-A1 | BIOSYNTHETICALLY GENERATED PYRROLINE-CARBOXY-LYSINE AND SITE SPECIFIC PROTEIN MODIFICATIONS VIA CHEMICAL DERIVATIZATION OF PYRROLINE-CARBOXY-LYSINE AND PYRROLYSINE RESIDUES | PTMS, PHYKPL, DNPEP | LPAR3 4238/4885LPAR2 4187/4885LPAR1 4025/4885 |
| US-20230287413-A1 | TARGETED DELIVERY OF AN INHIBITOR OF MIR-21 TO MACROPHAGES FOR THE TREATMENT OF PULMONARY FIBROSIS | MMP12, USP21, ACE2 | LPAR3 1408/4885LPAR2 1353/4885LPAR1 1005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.